JP2018522053A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522053A5
JP2018522053A5 JP2018506137A JP2018506137A JP2018522053A5 JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5 JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5
Authority
JP
Japan
Prior art keywords
combination
composition
tlr4 agonist
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522053A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/053290 external-priority patent/WO2017021792A1/en
Publication of JP2018522053A publication Critical patent/JP2018522053A/ja
Publication of JP2018522053A5 publication Critical patent/JP2018522053A5/ja
Pending legal-status Critical Current

Links

JP2018506137A 2015-08-06 2016-06-03 Tlr4アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用 Pending JP2018522053A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201912P 2015-08-06 2015-08-06
US62/201,912 2015-08-06
PCT/IB2016/053290 WO2017021792A1 (en) 2015-08-06 2016-06-03 Tlr4 agonists and compositions thereof and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2018522053A JP2018522053A (ja) 2018-08-09
JP2018522053A5 true JP2018522053A5 (cg-RX-API-DMAC7.html) 2019-07-04

Family

ID=56121139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506137A Pending JP2018522053A (ja) 2015-08-06 2016-06-03 Tlr4アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用

Country Status (10)

Country Link
US (1) US10765690B2 (cg-RX-API-DMAC7.html)
EP (1) EP3331565A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018522053A (cg-RX-API-DMAC7.html)
KR (1) KR20180032642A (cg-RX-API-DMAC7.html)
CN (1) CN108136024A (cg-RX-API-DMAC7.html)
AU (1) AU2016303387B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018002520A2 (cg-RX-API-DMAC7.html)
CA (1) CA2994790A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018107930A (cg-RX-API-DMAC7.html)
WO (1) WO2017021792A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
DK3752182T3 (da) 2018-02-12 2024-08-12 Inimmune Corp Toll-like receptor ligands
WO2020007760A1 (en) * 2018-07-03 2020-01-09 Glaxosmithkline Intellectual Property Development Limited Tlr4 compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions or formulations, methods of preparation, treatment or uses
WO2020031087A1 (en) * 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CN116457364A (zh) * 2020-11-11 2023-07-18 第一三共株式会社 新型氨基烷基氨基葡糖苷4-磷酸酯衍生物
CN117018195B (zh) * 2023-08-04 2024-05-21 中国人民解放军海军军医大学 小分子化合物或组合在制备启动肝脏原位再生药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
KR100829674B1 (ko) 2000-05-19 2008-05-16 코릭사 코포레이션 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법
US7129219B2 (en) 2000-08-04 2006-10-31 Corixa Corporation Immunoeffector compounds
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
ES2552243T3 (es) * 2008-12-23 2015-11-26 Glaxosmithkline Biologicals S.A. Miméticos del lípido A para su uso en la inducción de una respuesta inmunitaria
WO2010089411A2 (en) * 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
CA2798323A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
HK1214510A1 (zh) * 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法

Similar Documents

Publication Publication Date Title
JP2018522053A5 (cg-RX-API-DMAC7.html)
CL2021002995A1 (es) (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
JP2019521180A5 (cg-RX-API-DMAC7.html)
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
EP3356522A4 (en) COMPOSITIONS WITH PROTEIN-LOADED EXOSOME AND METHOD FOR THE PREPARATION AND RELEASE THEREOF
JP2013503174A5 (cg-RX-API-DMAC7.html)
NZ739902A (en) Multiligand agent for drug delivery
JP2019508440A5 (cg-RX-API-DMAC7.html)
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GEP20237470B (en) Magl inhibitors
WO2016098054A9 (en) Processes for preparing oxathiazin-like compounds
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
HRP20150530T1 (hr) Spojevi korisni za inhibiranje chk1
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
JP2013541586A5 (cg-RX-API-DMAC7.html)
TN2018000090A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
WO2015193517A3 (en) Liquid pharmaceutical composition comprising pemetrexed
WO2016130581A8 (en) Combination cancer therapy
CO6341557A2 (es) Derivados nitrogenados de la pancratistatina
EP3792253A4 (en) COMPOUND OF NOVEL STRUCTURE, COMPLEX, PHARMACEUTICAL COMPOSITION ANTI-CANCER AND ANTI-CANCER DRUG CONTAINING THEM